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Introduction
Perfusion process involves retention of the cells inside
t h eb i o r e a c t o rw h i l es i m u l t a n e o u s l yr e m o v i n gs p e n t
medium and adding fresh medium continuously. The
flow rate of addition of fresh and removal of spent med-
ium are generally kept the same (perfusion rate) to
maintain the culture volume inside the bioreactor. Cell
retention is possible with many devices but the reliabil-
ity and consistency in performance of these devices
remains a major challenge for design, operation and
scale-up of perfusion processes. For a filtration based
retention device, successful scale up depends on cell
retention efficiency, prevention of filter fouling and the
similarity of perfusion equipment between small and
l a r g es c a l e .W ep r e s e n tac a s es t u d yw h e r eap e r f u s i o n
process from a 2L (Liter) bioreactor is scaled up to
manufacturing scale of 1KL (Kilo Litre).
Materials and methods
A NS0 host cell line cultured in protein free medium
was used. At lab scale 2L stirred tank bioreactors with
internal spin filters as the retention device were used.
The 1KL production bioreactor used closed external
rotating filters for cell retention. Cell count and viability
were determined using Hemocytometer and Trypan
Blue dye exclusion. Glucose and lactate were measured
using YSI 2700 analyzer and product concentration by
Affinity chromatography.
Results and discussions
Development of perfusion process and scale up
A perfusion process was developed which consisted of a
batch phase for cell growth followed by perfusion phase
once the cell density reaches the desired level. This pro-
cess was scaled up by scaling up the scale dependent
parameters linearly same while maintaining the scale
independent factors within the acceptable range. The
filter parameters such as mesh type and filter area per
unit bioreactor volume were however not comparable
between the scales.
PB-1 (Production Batch no. 1)
T h eg r o w t hr a t ed u r i n gt h eb a t c hp h a s eo ft h er u nw a s
comparable to the lab scale. However, during the perfu-
sion phase, the maximum cell density was observed to
be only about 25% of the lab scale. Due to the lower
cell counts, the perfusion rates were also proportionally
reduced. Together this resulted in obtaining only ~25%
of the expected product yield.
As part of investigation, the following factors were
analyzed:
a) Inoculum and “medium lot” used in PB-1 – Ac o n -
trol batch was run in the lab with the same inoculum
and medium as used in the PB-1 run. This batch
showed normal lab batch profiles ruling out these fac-
tors as possible cause for the underperformance of the
production batch.
b) Pumps used for perfusion – The lab scale used
peristaltic pumps while in manufacturing pulsating
pumps were used. These pulsating pumps could influ-
ence cell retention and hence were replaced with peri-
staltic pumps for future production batches.
PB-2 (Production Batch no. 2)
Changing the pump type resulted in better cell reten-
tion. However, soon the retention started dropping,
indicating cell loss from the bioreactor. Visual inspec-
tion of the filter mesh (mesh Type A) showed significant
mesh deformation. This could have resulted due to the
fragile nature of the mesh which could not withstand
the negative pressure generated inside the closed filter
housing due to suction forces and filter fouling. The
mesh Type A was also found to be fouling very fast due
to it mesh weave design. Two other mesh types (B & C)
with different mesh weave patterns and mechanical
strengths were evaluated. Type B showed poor cell * Correspondence: ankur.bhatnagar@biocon.com
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cell retention and also did not deform easily during filter
fouling. Thus the filter mesh was changed from Type A
to Type C in the production system.
PB-3 (Production Batch no. 3)
The filter with mesh C showed cell retention better than
even the lab scale. This resulted in achieving cell densi-
ties higher than the range of the lab batches (Figure 1).
The perfusion rates were increased by about 20% from
the lab scale to address the nutritional requirements of
the higher cell numbers. The product yield was also
proportionally higher by ~20%.
Note: N. VCC – normalized viable cell concentration
Product quality analysis
Analysis showed that the product obtained from batch
PB-3 was significantly different in quality (charge distri-
bution) compared to product from PB-1,2 and lab
batches. The following were evaluated as possible rea-
sons for the observed differences:
a) High perfusion rates compared to lab and PB-1,2
batches resulting in shorter product residence time
inside the bioreactor.
b) Different lactate and pCO2 levels maintained (due
to higher perfusion rates) which also resulted in differ-
ent pH profiles.
PB-4 (Production Batch no. 4)
Batch PB-4 was run with perfusion flow rates compar-
able to the lab batches. The additional nutritional
requirement for the higher cell concentration was
addressed by making the fresh medium more concen-
trated. pH was also controlled using the CO2 and base
combination. The cell concentration obtained was simi-
lar to PB-3. Lowering the perfusion flow rates also
helped in delaying the clogging of the filter.
Product analysis showed that the changes done in the
batch helped in bringing the product quality closer to
(within acceptable range) the lab batches. The results
are shown in the Table 1. Two differently charged spe-
cies Type-1 and Type-2 are used for comparison.
Summary
Development and scale-up of a perfusion process has
challenges due to the complex nature of the process and
unavailability of direct scale-up of the perfusion equip-
ment. The initial scale-up to production scale resulted
in poor cell growth profile. Upon investigation, the rea-
son for low cell concentration was attributed to poor
cell retention by the perfusion device. Changes were
introduced in the type of mesh used for filter construc-
tion and perfusion pumps to improve retention. These
modifications helped in better cell culture profiles and
yields. However, the product quality was impacted
Figure 1 Cell count profiles from the lab batches and the production batches with different mesh types.
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sion flow rates were done to address the product quality
differences.
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Table 1 Product quality comparison of PB-3 and PB-4
batches.
Perfusion lots PB-3 PB-4
Type-1* Type-2* Type-1* Type-2*
1 112 74 59 139
2 47 184 66 126
3 43 195 73 116
4 41 198 73 120
5 39 208 82 109
6 39 209 82 118
* % of Lab batch profiles.
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